BIND Therapeutics to be Added to Russell Indexes on December 20, 2013

CAMBRIDGE, Mass.--()--BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced today that it will be added as a member of the Russell 2000®, Russell 3000®, Russell Global and Russell Microcap Indexes at the close of market today, December 20, 2013, as Russell Investments reconstitutes its comprehensive family of global indexes.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. The Russell 2000® Index measures the performance of the small-cap segment of the U.S. equity universe and is a subset of the Russell 3000® Index, which measures the performance of the largest 3,000 U.S. companies. Members of the Russell 2000® Index are also included in the Russell Global Index. The Russell Microcap Index measures the performance of the microcap segment of the U.S. equity market. Microcap stocks make up less than 3% of the U.S. equity market (by market cap) and consist of the smallest 1,000 securities in the small-cap Russell 2000® Index, plus the next smallest eligible securities by market cap.

About BIND Therapeutics

BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, its novel targeted therapeutics. BIND intends to leverage its Medicinal Nanoengineering® platform to develop a pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. BIND’s lead drug candidate, BIND-014, is an Accurin that targets PSMA and contains docetaxel, a clinically-validated and widely used cancer chemotherapy drug. BIND-014 is currently in Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer. BIND has announced collaborations with Amgen Inc., Pfizer Inc. and AstraZeneca AB to develop Accurins based on therapeutic payloads from their product pipelines. BIND’s platform originated from the pioneering nanotechnology research at the Massachusetts Institute of Technology and Brigham and Women’s Hospital/Harvard Medical School of BIND’s scientific founders and directors Dr. Robert Langer and Dr. Omid Farokhzad. For more information, please visit the company's web site at www.bindtherapeutics.com.

Contacts

The Yates Network
Gina Nugent, 617-460-3579
gina@theyatesnetwork.com

Release Summary

BIND added as a member of the Russell 2000®, Russell 3000®, Russell Global and Microcap Indexes at the close of market December 20, 2013

Sharing

Contacts

The Yates Network
Gina Nugent, 617-460-3579
gina@theyatesnetwork.com